PPAR-γ Impairment Alters Peroxisome Functionality in Primary Astrocyte Cell Cultures

Figure 5

Catalase expression: effect of G3335. Astrocytes (5 ⋅ 10⁵ cells/well) were treated with the reversible PPAR𝛾 antagonist G3335 (30 μM) for 2 days or 5 days, in the absence or presence of the PPAR𝛾 agonist rosiglitazone (100 μM). Values are expressed as the mean ± S.E.M. percent of control of three experiments. Control condition was arbitrarily set as 100%. *𝑃<0.05 in comparison to control conditions in the absence of treatment; ^∧𝑃<0.05 in comparison to G3335 treatment on day 5.